Literature DB >> 31358101

An Audit of Caesarean Section Rate Using Modified Robson Criteria at a Tertiary Care Hospital.

Asma Ansari1, Shehla Baqai2, Rabia Imran2.   

Abstract

OBJECTIVE: To evaluate the rising rate of caesarean section (CS) and its contributing factors at a tertiary care hospital. STUDY
DESIGN: Clinical audit. PLACE AND DURATION OF STUDY: Obstetrics and Gynecology Department, Pak Emirates Military Hospital (PEMH), Rawalpindi, from January to December 2017.
METHODOLOGY: All caesarean sections were classified according to modified Robson criteria into twelve groups, after modification. The size of each group, rate of caesarean section and contribution of each group was calculated. A re-audit was carried out after 6 months under the same protocol thus completing the audit cycle.
RESULTS: CS rate was 54% (n=3878). The maximum contribution 27.42% (n=1976) to total CS rate was made by Group 5, 12.07% (n=870) by group 12 and 7.34% (n=531) by group 2. Re-audit showed a reduced CS rate of 38.2% (n=1342) with contribution by Group 5 reduced to 16.05% (n=563), Group 12 to 7.47% (n=262) and Group 2 reduced to 5.7% (n=202), respectively.
CONCLUSION: Modified Robson Criteria is an effective auditing tool which identifies the exact areas where efforts and strategies are required to reduce the overall CS rate.

Entities:  

Mesh:

Year:  2019        PMID: 31358101     DOI: 10.29271/jcpsp.2019.08.768

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  2 in total

1.  Cesarean Audit Using Robson Classification at a Tertiary Care Center in Bihar: A Retrospective Study.

Authors:  Pammy Pravina; Ranjana Ranjana; Neeru Goel
Journal:  Cureus       Date:  2022-03-13

2.  To evaluate rising caesarean section rate and factors contributing to it by using Modified Robson's Criteria at a tertiary care hospital.

Authors:  Erum Majid; Shazia Kulsoom; Sara Fatima; Bader Faiyaz Zuberi
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.